Treating desires not diseases: a pill for every ill and an ill for every pill?

Drug Discovery Today

Volumn 12, Issue 3-4, 2007, Pages 161-166

  Triggle, David J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CLOMICALM; INDOLEBANT; NEUROTROPIC AGENT; OLANZAPINE; RISPERIDONE; SELEGILINE; SILDENAFIL; SULFAPYRIDINE; TERBINAFINE; UNCLASSIFIED DRUG;

ADVERTIZING; CONSUMER; DOG DISEASE; DRUG INDUSTRY; DRUG MARKETING; FEMALE SEXUAL DYSFUNCTION; GENOMICS; GOVERNMENT REGULATION; HUMAN; INFORMATION SCIENCE; MOTIVATION; MOTIVATIONAL DEFICIENCY DISORDER; NEUROLOGIC DISEASE; OBESITY; PATENT; PILL; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; REVIEW; RISK FACTOR; SCORING SYSTEM; TOENAIL ONYCHOMYCOSIS;

DRUG INDUSTRY; ETHICS, PROFESSIONAL; HUMANS; LOBBYING; MARKETING; ONYCHOMYCOSIS; RESTLESS LEGS SYNDROME; TERMINOLOGY;

EID: 33846687085     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2006.12.001     Document Type: Review

References (55)

1. Moynihan R. Scientists find new disease: motivational deficiency disorder. BMJ 332 (2006) 745
2. Murray J.L., et al. Eight Americas: investigating mortality disparities across races, counties and race-counties in the United States. PloS Med. 3 (2006) e260 10.1371/journal.pmed.0030260
3. Callahan D., and Wasunna A.A. Medicine and the Market. Equity vs Choice (2006), Johns Hopkins University Press
4. Mahar M. Money-driven Medicine (2006), Collins
5. Smith A. The Wealth of Nations (1776), Modern Library
6. Buchan J. The Authentic Adam Smith (2006), Norton
7. Friedman M. Capitalism and Freedom (2002), University of Chicago Press
8. Dreyfuss B.T. Poison pill. Wash. Mon. 38 (2006) 23-29
9. Berenson, A. (2006) As drug prices climb, democrats find fault with medicare plan. New York Times 6 November
10. Sarasohn, J (2004) Tauzin to head drug trade group. Washington Post 16 December
11. Freudenheim, M. (2006) Market place; a windfall from shifts to medicare. New York Times 18 July
12. Triggle D.J. Medicines in the 21st century: pills, politics, potions and profits: where is public policy?. Drug Dev. Res. 59 (2003) 269-291
13. Angell M. The Truth about Drug Companies (2004), Random House
14. Avorn J. Powerful Medicines (2004), Knopf
15. Kassirer J.P. On the Take (2005), Oxford University Press
16. Muller J.Z. The Mind and the Market (2002), Anchor Books
17. Moynihan R., et al. Selling sickness: the pharmaceutical industry and disease mongering. BMJ 324 (2002) 886-891
18. Triggle D.J. Vaccines, Viagra and Vioxx: medicines, markets and money - when life-saving meets life-style. Drug Dev. Res. 64 (2005) 90-98
19. Blech J. Inventing Disease and Pushing Pills (2006), Routledge
20. Moynihan R., and Cassels A. Selling Sickness (2005), Nation Books
21. Laumann E.O. Sexual dysfunction in the United States: prevalence and predictors. J. Am. Med. Assoc. 281 (1999) 537-542
22. Bartlett A.A. Forgotten fundamentals of the energy crisis. Am. J. Phys. 46 (1978) 876-888
23. Class S. Pharma reformulates. Chem. Eng. News 5 (2005) 15-32
24. Tsai A.C. Conflicts between commercial and scientific interests in pharmaceutical advertising for medical journals. Int. J. Health Serv. 33 (2003) 751-768
25. Fugh-Berman A., et al. Advertising in medical journals: should current practices change?. PloS Med. 3 (2006) e130 10.1371/journal.pmed.0030130
26. Gilsdorf J.R. As drug marketing pays off, my mother pays up. Health Aff. 23 (2004) 208-212
27. In: Baciu A., et al. (Ed). The Future of Drug Safety: Promoting and Protecting the Health of the Public (2006), Institute of Medicine
28. Harris, G. (2006) Study condemns F.D.A.'s handling of drug safety. New York Time, 23 September
29. Young, A. (2006) Exodus, morale shake CDC. Prominent leaders are leaving the agency in droves, restructuring has morale on the decline, and federal funds have been shifted. Current and former staff say someone has to stop the bleeding. Atlanta Journal Constitution 10 September
30. Editorial. An ailing agency. Nature 443 (2006) 245
31. Mooney C. The Republican War on Science (2005), Perseus Books
32. Polanyi K. The Great Transformation (1944), Beacon Press
33. Lyon, J. (2006) Spin doctor. Chicago Tribune (magazine section) 2 July
34. Graham D.J. COX-2 inhibitors, other NSAIDs, and cardiovascular risk. J. Am. Med. Assoc. 296 (2006) 1653-1656
35. Clayton, V. (2006) Seeking straight As, parents push for pills. MSNBC 7 September
36. Olfson M., et al. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch. Gen. Psychiatry 63 (2006) 679-685
37. In: McGinnis J.M., et al. (Ed). Food Marketing to Children and Youth: Threat or Opportunity? (2006), Institute of Medicine, National Academies Press
38. Nestle M. Food marketing and childhood obesity - a matter of policy. N. Engl. J. Med. 354 (2006) 2527-2529
39. Allen R.P., et al. Restless legs syndrome prevalence and impact. Arch. Intern. Med. 165 (2005) 1286-1292
40. Woloshin A., and Schwartz L.M. Giving legs to restless legs: a case study of how the media helps make people sick. PloS Med. 3 (2006) e130 10.1371/journal.pmed.0030130
41. Lexchin J. Bigger and better: how Pfizer redefined erectile dysfunction. PloS Med. 3 (2006) e132 10.1371/journal.pmed.0030132
42. Addis L.B., et al. Sexual activity and function in middle-aged and older women. Obstet. Gynecol. 107 (2006) 755-764
43. Mayor S. Pfizer will not apply for a license for sildenafil for women. BMJ 328 (2004) 542
44. Tiefer L. Female sexual dysfunction: a case study of disease mongering and activist resistance. PloS Med. 3 (2006) e178 10.1371/journal.pmed.0030178
45. Hartley H. The 'pinking' of Viagra culture: drug industry efforts to create and repackage sex drugs for women. Sexualities 9 (2006) 362
46. Gierhart B.D. When does a 'less than perfect' sex life become female sexual dysfunction?. Obstet. Gynecol. 107 (2006) 750-751
47. Fishman J.R. Manufacturing desire: The commodification of female sexual dysfunction. Soc. Stud. Sci. 34 (2006) 187-218
48. Stiglitz J. Making Globalization Work (2006), Norton
49. Stiglitz, J. (2006) Give prizes not patents. New Sci. 26 September, p. 21
50. Munos B. Can open-source R&D reinvigorate drug research?. Drug Discov. Today 5 (2006) 723-729
51. Merton, R. (1942) The ethos of science. J. Legal and Political Sociology 1, 115-126. Reprinted in: Merton, R.K. (1996) On Social Structure and Science (Sztompka, P., ed.), pp. 267-276, University of Chicago Press
52. Saul, S. (2006) Drug maker fires chief of 5 years. New York Times 13 September
53. Shuchman M. Delaying generic competition - corporate payoffs and the future of Plavix. N. Engl. J. Med. 355 (2006) 1297-1300
54. Diamond J. The Irritable Male Syndrome (2005), Holtzbrinck
55. Marcus S. The Other Victorians: A Study of Sexuality and Pornography in mid-Victorian England (1977), Plume